Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- University Cancer and Blood Center LLC — Athens, Georgia
- Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Piedmont Hospital — Atlanta, Georgia
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Emory Decatur Hospital — Decatur, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Piedmont Hospital — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- WellStar Cobb Hospital — Austell, Georgia
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Georgia: - Research Site — Atlanta, Georgia
- Research Site — Atlanta, Georgia
- Research Site — Columbus, Georgia
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Georgia: - Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0040) — Thomasville, Georgia
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Georgia: - Atlanta Cancer Care - Northside Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Georgia: - Clinical Trial Site — Marietta, Georgia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Georgia: - Local Institution - 0294 — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Georgia: - Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032) — Thomasville, Georgia
Phase 3 Recruiting Network
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…
Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Sites in Georgia: - Emory Proton Therapy Center — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Georgia: - Winship Cancer Institute, Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in Georgia: - Winship Cancer Institute, Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…
Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
- Georgia Cancer Center at Augusta University — Augusta, Georgia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this stud…
Sponsor: Gilead Sciences
NCT ID: NCT06926920
Sites in Georgia: - Winship Cancer Institute - Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Georgia: - Emory - Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Sponsor: Massachusetts General Hospital
NCT ID: NCT03990896
Sites in Georgia: - Emory University Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It …
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05919108
Sites in Georgia: - Emory University/ Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of m…
Sponsor: Reshma L. Mahtani, D.O.
NCT ID: NCT06263543
Sites in Georgia: - Winship Cancer Institute at Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characteri…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07288359
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Sponsor: Yale University
NCT ID: NCT06750484
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
Sponsor: ProDa BioTech, LLC
NCT ID: NCT06460298
Sites in Georgia: - Emory University Winship Cancer Institute — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalati…
Sponsor: Eli Lilly and Company
NCT ID: NCT06400472
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy i…
Sponsor: Regor Pharmaceuticals Inc.
NCT ID: NCT05304962
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in Georgia: - Emory University, Winship Cancer Institute — Atlanta, Georgia